{"id":24212,"date":"2022-11-18T23:31:00","date_gmt":"2022-11-18T15:31:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24212"},"modified":"2025-01-30T23:35:57","modified_gmt":"2025-01-30T15:35:57","slug":"mirati-therapeutics-sues-inventisbio-over-trade-secret-misappropriation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24212","title":{"rendered":"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation"},"content":{"rendered":"\n

US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382<\/a>) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents. Mirati is seeking damages of RMB 99 million (USD 14 million).<\/p>\n\n\n\n

Lawsuit Details<\/strong>
Mirati specifically alleges that certain patents awarded to InventisBio for a preclinical project infringe on Mirati\u2019s own research and should be owned by Mirati. The lawsuit highlights the ongoing legal disputes in the biotechnology sector, where intellectual property rights are a critical asset.<\/p>\n\n\n\n

Company Profiles<\/strong>
Both Mirati and InventisBio focus on the development of targeted small-molecule therapies for cancer and other therapeutic areas. Mirati\u2019s lead pipeline candidate is the KRASG12C-targeted adagrasib (MRTX849), while its preclinical\/discovery candidates include an SOS1 Inhibitor (KRAS signal modifying) and a mutant KRAS inhibitor. Meanwhile, InventisBio\u2019s pipeline includes molecules targeting EGFR, KRASG12C, SERD, and others. This legal action underscores the competitive landscape in oncology research and the importance of protecting intellectual property.<\/p>\n\n\n\n

Future Implications<\/strong>
The lawsuit between Mirati and InventisBio highlights the complexities of intellectual property disputes in the global biotechnology industry. As both companies continue to advance their pipelines, the outcome of this case could have significant implications for their respective development strategies and market positions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[682,2124,1495,33],"class_list":["post-24212","post","type-post","status-publish","format-standard","hentry","category-company","category-legal-ip","tag-inventisbio","tag-mirati-therapeutics","tag-sha-688382","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nMirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents. Mirati is seeking damages of RMB 99 million (USD 14 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24212\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24212\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-18T15:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-30T15:35:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24212#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24212\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation\",\"datePublished\":\"2022-11-18T15:31:00+00:00\",\"dateModified\":\"2025-01-30T15:35:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24212\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"InventisBio\",\"Mirati Therapeutics\",\"SHA: 688382\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24212#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24212\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24212\",\"name\":\"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-18T15:31:00+00:00\",\"dateModified\":\"2025-01-30T15:35:57+00:00\",\"description\":\"US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents. Mirati is seeking damages of RMB 99 million (USD 14 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24212#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24212\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24212#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation - Insight, China's Pharmaceutical Industry","description":"US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents. Mirati is seeking damages of RMB 99 million (USD 14 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24212","og_locale":"en_US","og_type":"article","og_title":"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24212","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-18T15:31:00+00:00","article_modified_time":"2025-01-30T15:35:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24212#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24212"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation","datePublished":"2022-11-18T15:31:00+00:00","dateModified":"2025-01-30T15:35:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24212"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["InventisBio","Mirati Therapeutics","SHA: 688382","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24212#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24212","url":"https:\/\/flcube.com\/?p=24212","name":"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-18T15:31:00+00:00","dateModified":"2025-01-30T15:35:57+00:00","description":"US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents. Mirati is seeking damages of RMB 99 million (USD 14 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24212#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24212"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24212#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24212"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24212\/revisions"}],"predecessor-version":[{"id":24214,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24212\/revisions\/24214"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}